Inventor · disambiguated record
Tobias Marquardt
Also filed as: MARQUARDT TOBIAS
20 granted patents·18 pending applications·36 citations·filing 2007–2025
91Inventor score
Top patents by PatentIndex Score
38 records- 0185US10435403B2Positive allosteric modulators of muscarinic M2 receptorBayer Pharma AG·Filed 2016·Granted Oct 8, 2019·7 cites·8 claims
- 0281US9340528B2Substituted aminoquinoxalines as tyrosine threonine kinase inhibitorsBADER BENJAMIN·Filed 2010·Granted May 17, 2016·12 cites·6 claims
- 0380US11166932B2Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereofBayer Pharma AG·Filed 2016·Granted Nov 9, 2021·2 cites·16 claims
- 0478US10150773B2N-substituted 8-[(2,6-difluorobenzyl)oxy]-2,6- dimethylimidazo[1,2-a]pyrazin-3-carboxamide derivatives as stimulators of soluble guanylate cyclase (SGC) for the treatment of cardiovascular diseasesBayer Pharma AG·Filed 2016·Granted Dec 11, 2018·3 cites·8 claims
- 0578US9422285B2Substituted pyrazolo[1,5-A]-pyridine-3-carboxamides and use thereofBayer Pharma AG·Filed 2014·Granted Aug 23, 2016·4 cites·13 claims
- 0677US9605008B2Benzyl-1H-pyrazolo[3,4-b]pyridines and use thereofBayer Pharma AG·Filed 2014·Granted Mar 28, 2017·3 cites·24 claims
- 0774US10519154B27-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereofBayer Pharma AG·Filed 2017·Granted Dec 31, 2019·2 cites·14 claims
- 0872US12427131B2Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereofBayer Pharma AG·Filed 2021·Granted Sep 30, 2025·0 cites·8 claims
- 0972US10927109B27-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereofBAYER AG·Filed 2017·Granted Feb 23, 2021·1 cites·19 claims
- 1072US2022041752A1Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)BAYER HEALTHCARE LLC·Filed 2021·Application pending·0 cites
- 1167US2018194857A1Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)BAYER HEALTHCARE LLC·Filed 2018·Application pending·0 cites
- 1266US2019194353A1Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)BAYER HEALTHCARE LLC·Filed 2018·Application pending·0 cites
- 1365US9688699B23-(pyrimidine-2-yl)imidazo[1,2-a]pyridinesBayer Pharma AG·Filed 2015·Granted Jun 27, 2017·1 cites·11 claims
- 1461US8729082B2Substituted imidazoquinoxalinesKOPPITZ MARCUS·Filed 2010·Granted May 20, 2014·1 cites·13 claims
- 1561US2025361282A1Atrial natriuretic peptide engrafted antibodiesBAYER AG·Filed 2025·Application pending·0 cites
- 1659US12331094B2Atrial natriuretic peptide engrafted antibodiesBAYER AG·Filed 2019·Granted Jun 17, 2025·0 cites·18 claims
- 1759US11472803B27-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereofBAYER AG·Filed 2021·Granted Oct 18, 2022·0 cites·3 claims
- 1859US2017107298A1Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)BAYER HEALTHCARE LLC·Filed 2016·Application pending·0 cites
- 1954US2014294832A1Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)WANG ZHUOZHI·Filed 2012·Application pending·0 cites
- 2051US2019367516A1Positive allosteric modulators of muscarinic m2 receptorBayer Pharma AG·Filed 2019·Application pending·0 cites
- 2145US2010105673A1Substituted aminofuranones and their useBAYER SCHERING PHARMA AG·Filed 2007·Application pending·0 cites
- 2242US10214526B2Substituted pyrazolo[1,5-a]-pyridine-3-carboxamides and use thereofBayer Pharma AG·Filed 2016·Granted Feb 26, 2019·0 cites·18 claims
- 2341US2015307625A1MONOCLONAL ANTIBODIES AGAINST ACTIVATED PROTEIN C (aPC)BAYER HEALTHCARE LLC·Filed 2013·Application pending·0 cites
- 2440US9714266B2Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (AKR1C3)Bayer Pharma AG·Filed 2014·Granted Jul 25, 2017·0 cites·10 claims
- 2539US9512169B23-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicamentsBayer Pharma AG·Filed 2013·Granted Dec 6, 2016·0 cites·10 claims
- 2636US10292970B2Heteroaryl-substituted imidazo[1,2-A]pyridines and their useBayer Pharma AG·Filed 2015·Granted May 21, 2019·0 cites·6 claims
- 2736US10174021B2Substituted pyrazolo[1,5-A]pyridines and their useBayer Pharma AG·Filed 2015·Granted Jan 8, 2019·0 cites·7 claims
- 2836US9487554B2Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, processes for their preparation, pharmaceutical preparations comprising them and their use for preparing medicamentsBAYER IP GMBH·Filed 2012·Granted Nov 8, 2016·0 cites·8 claims
- 2935US2017101407A16-chlorine-substituted imidazo[1,2-a]pyridine carboxamides and the use thereof as soluble guanylate cyclase stimulatorsBayer Pharma AG·Filed 2015·Application pending·0 cites
- 3035US2017050962A1Imidazo[1,2-a]pyridines as stimulators of soluble guanylate cyclase for treating cardiovascular diseasesBayer Pharma AG·Filed 2015·Application pending·0 cites
- 3134US9771360B2Cyano-substituted imidazo[1,2-A]pyridinecarboxamides and their useBayer Pharma AG·Filed 2015·Granted Sep 26, 2017·0 cites·7 claims
- 3234US2017233345A1Substituted quinoline-4-carboxamides and use thereofBayer Pharma AG·Filed 2015·Application pending·0 cites
- 3334US2017240566A1Amino-substituted annulated pyrimidines and use thereofBayer Pharma AG·Filed 2015·Application pending·0 cites
- 3434US2017233413A1Substituted annulated pyrimidines and use thereofBayer Pharma AG·Filed 2015·Application pending·0 cites
- 3534US2017057958A1Enantiomers of the n-(2-amino-5-fluoro-2-methylpentyl)-8-[(2,6-difluorobenzyl)oxy]-2-methylimidazo[1,2-a]pyridine-3-carboxamide, as well as of the di- and trifluoro derivatives for the treatment of cardiovascular diseasesBayer Pharma AG·Filed 2015·Application pending·0 cites
- 3633US2013121994A1Triazolopyridine derivativesKOPPITZ MARCUS·Filed 2010·Application pending·0 cites
- 3733US2017050961A1Imidazo[1,2-a]pyridines as soluble guanylate cyclase stimulators for the treatment of cardiovascular diseasesBayer Pharma AG·Filed 2015·Application pending·0 cites
- 3833US2017057954A1Substituted imidazo[1,2-a]pyridinecarboxamides and their useBayer Pharma AG·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Tobias Marquardt files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →